A potassium binder helped patients with heart failure (HF) who have or are at high risk for hyperkalemia stay on spironolactone at an optimal dose, but showed a signal of HF hospitalization risk, researchers reported.

For the REALIZE-K trial, presented at the American Heart Association Scientific Sessions and simultaneously published in the Journal of the American College of Cardiology, Mikhail Kosiborod, MD, FACC, FAHA, cardiologist and vice president of research at Saint Luke’s Mid America Heart Institute and professor of medicine at the University of Missouri-Kansas City School of Medicine, and colleagues randomly assigned 203 patients with HF with reduced ejection fraction and hyperkalemia or elevated risk for it to spironolactone plus the potassium binder sodium zirconium cyclosilicate or to spironolactone plus placebo.

Read the full Healio article: Potassium Binder Helps Optimize Spironolactone Use in Patients with HF, Hyperkalemia Risk